Search results
US FDA approves Bristol-Myers' lung cancer drug
Reuters via AOL· 6 months agoThe drug, to be sold under the brand name Augtyro, is set to compete in a crowded market for lung cancer treatments that includes Bristol Myers' other...
Bristol Myers to acquire brain drug developer Karuna for $14B
BioPharma Dive via Yahoo Finance· 4 months agoThe deal would hand Bristol Myers, which is reprioritizing neuroscience research, an experimental...
Bristol Myers wins dismissal of a $6.4 billion lawsuit over cancer drug delay
Reuters via Yahoo News· 1 year agoNEW YORK (Reuters) -A U.S. judge on Wednesday dismissed a lawsuit accusing Bristol Myers Squibb Co...
A Patent Cliff Is Coming For Bristol Myers — Can Billions In New Products Fill The Gap?
Investor's Business Daily· 1 year agoIt's a new day at Bristol Myers Squibb, according to a company executive. But BMY stock remains...
Bristol Myers must face $6.4 billion lawsuit over delayed cancer drug
Reuters via Yahoo Finance· 2 years agoA U.S. judge on Friday refused to dismiss a $6.4 billion lawsuit accusing Bristol Myers Squibb Co of...
US FDA allows J&J, Bristol Myers cell therapies as early cancer treatments (April 5)
Reuters via AOL· 4 weeks agoThe U.S. Food and Drug Administration has allowed the cell therapies of Johnson & Johnson and...
Bristol-Myers Squibb to acquire Mirati in up to $5.8 billion deal
Reuters via Yahoo Finance· 7 months agoBristol-Myers Squibb aims to diversify its oncology business and add drugs it hopes can help offset...
FDA approves new Bristol Myers drug for lung cancer
BioPharma Dive via Yahoo Finance· 6 months agoAcquired via a $4 billion biotech buyout, Augtyro is one of an array of new products the pharma hopes will offset patent expirations for current top...
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
Motley Fool· 5 months agoOn Nov. 28, the Food and Drug Administration (FDA) announced that it was opening an investigation...
Is Bristol Myers Squibb Stock a Buy With Its New-Product Sales Soaring?
Motley Fool· 2 years agoBristol Myers Squibb's management team was quick to point to the strong performance of several new...